A preclinical study revealed that ABL001 was active in inhibiting all BCR-ABL1 positive CML cell lines and xenografted mice models derived from either the KCL-22 cell line or primary cells of Ph+ ALL patients (26). The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.